Leerink Partners Rates Quince Therapeutics (QNCX) buy

Analysts Set New Price Targets

On June 24, 2026, analyst Joseph Schwartz at Leerink Partners reiterated a buy rating on Quince Therapeutics, Inc. (NasdaqGS: QNCX) along with a $4 price target. This call is part of a series of updates from major financial firms tracking the biotechnology firm's pipeline progress. Other institutions have also weighed in on the shares over recent months with various targets and recommendations.

Wall Street Coverage and Price Targets

A number of other firms have shared their outlooks on the biotechnology firm through the summer and fall. On June 23, 2026, Cantor Fitzgerald initiated coverage with an overweight rating and a $4 price target. Later in the summer, Cantor Fitzgerald returned on August 18, 2026 to reiterate its overweight rating with a $70 price target. Oppenheimer joined the group on July 29, 2026 with an outperform rating and an $82 price target. Citizens followed on September 22, 2026, upgrading the stock to a market outperform rating with a $77 price target. Rodman & Renshaw started coverage on September 24, 2026 with a buy rating and a $70.00 price target. Most recently, on October 9, 2026, Raymond James initiated coverage on the stock with an outperform rating and a $72 price target. Across the wider street, the company carries a strong buy consensus from six analysts, with price targets ranging from a low of $65 up to a high of $98 and a mean target of $75.17.

Stock Market Context

Quince Therapeutics trades on the NasdaqGS under the ticker QNCX, recently changing hands around $0.94 per share. The company has a market capitalization of $31.5 million. Because the firm is not currently profitable, it has no meaningful price-to-earnings ratio to display.

Company Pipeline and Focus

Quince Therapeutics is a clinical-stage biotechnology firm located in South San Francisco, California. Led by CEO Dr. Dirk Thye, the team of 38 employees focuses on acquiring, developing, and commercializing treatments for patients who suffer from rare and debilitating conditions. Its lead drug candidate, eDSP, is currently in Phase 3 clinical testing for a rare pediatric neurodegenerative and immunodeficiency disorder known as Ataxia-Telangiectasia. The business also uses its AIDE technology platform to encapsulate therapeutics inside a patient's own red blood cells through an automated process using specialized single-use kits.

Upcoming Financial Updates

Market participants continue to monitor how the clinical pipeline develops alongside the company's financial results. Investors will look toward the firm's next scheduled earnings report on November 12, 2026, for updates on its research spending and cash reserves.